MX2011008876A - Metabolitos analogos de ceramida. - Google Patents
Metabolitos analogos de ceramida.Info
- Publication number
- MX2011008876A MX2011008876A MX2011008876A MX2011008876A MX2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A
- Authority
- MX
- Mexico
- Prior art keywords
- ceramide
- relates
- metabolites
- analogous
- analogous metabolites
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical class CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 3
- 230000001363 autoimmune Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09153550 | 2009-02-24 | ||
| PCT/EP2010/052231 WO2010097371A1 (en) | 2009-02-24 | 2010-02-23 | Ceramide-analogous metabolites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008876A true MX2011008876A (es) | 2011-09-21 |
Family
ID=40447014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008876A MX2011008876A (es) | 2009-02-24 | 2010-02-23 | Metabolitos analogos de ceramida. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8673982B2 (enExample) |
| EP (1) | EP2400960B1 (enExample) |
| JP (1) | JP2012518671A (enExample) |
| KR (1) | KR20110126631A (enExample) |
| CN (1) | CN102333530A (enExample) |
| AU (1) | AU2010217605B2 (enExample) |
| BR (1) | BRPI1007994A2 (enExample) |
| CA (1) | CA2752003A1 (enExample) |
| ES (1) | ES2411138T3 (enExample) |
| MX (1) | MX2011008876A (enExample) |
| PL (1) | PL2400960T3 (enExample) |
| PT (1) | PT2400960E (enExample) |
| RU (1) | RU2011138963A (enExample) |
| WO (1) | WO2010097371A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2888634C (en) * | 2012-10-19 | 2019-10-08 | Ruth Perez | Compositions and methods for the treatment of parkinson's disease |
| WO2014084676A1 (ko) * | 2012-11-30 | 2014-06-05 | (주)아모레퍼시픽 | 신규한 유사 세라마이드 화합물 및 그 제조방법 |
| EP2964210B1 (en) * | 2013-03-05 | 2023-10-04 | Biocon Limited | A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof |
| KR101510683B1 (ko) | 2013-09-03 | 2015-04-10 | (주)네오팜 | 카나비노이드 수용체에 길항작용을 가지는 신규한 유사 세라마이드 유도체 및 이를 포함하는 약학 또는 화장품 조성물 |
| EP3118621A1 (en) | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2579602B2 (ja) * | 1992-10-21 | 1997-02-05 | 吉富製薬株式会社 | ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤 |
| DE69524962D1 (de) * | 1994-08-22 | 2002-02-14 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| US5948820A (en) * | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
| RU2402324C2 (ru) * | 2004-07-30 | 2010-10-27 | Новартис Аг | Композиции на основе соединений 2-амино-1,3-пропандиола |
| GT200600350A (es) * | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| CN101346346B (zh) * | 2005-12-15 | 2012-08-22 | 田边三菱制药株式会社 | 胺化合物及其医药用途 |
| CN101240002B (zh) * | 2007-02-07 | 2011-01-26 | 首都医科大学 | 脂肪酰氨基酰阿糖胞苷缀合物、其制备方法和应用 |
-
2010
- 2010-02-23 PL PL10705160T patent/PL2400960T3/pl unknown
- 2010-02-23 EP EP10705160.9A patent/EP2400960B1/en not_active Not-in-force
- 2010-02-23 ES ES10705160T patent/ES2411138T3/es active Active
- 2010-02-23 PT PT107051609T patent/PT2400960E/pt unknown
- 2010-02-23 BR BRPI1007994A patent/BRPI1007994A2/pt not_active IP Right Cessation
- 2010-02-23 CA CA2752003A patent/CA2752003A1/en not_active Abandoned
- 2010-02-23 RU RU2011138963/15A patent/RU2011138963A/ru not_active Application Discontinuation
- 2010-02-23 WO PCT/EP2010/052231 patent/WO2010097371A1/en not_active Ceased
- 2010-02-23 US US13/202,939 patent/US8673982B2/en not_active Expired - Fee Related
- 2010-02-23 KR KR1020117019540A patent/KR20110126631A/ko not_active Withdrawn
- 2010-02-23 JP JP2011551479A patent/JP2012518671A/ja active Pending
- 2010-02-23 AU AU2010217605A patent/AU2010217605B2/en not_active Ceased
- 2010-02-23 MX MX2011008876A patent/MX2011008876A/es not_active Application Discontinuation
- 2010-02-23 CN CN2010800089918A patent/CN102333530A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2400960E (pt) | 2013-06-28 |
| EP2400960B1 (en) | 2013-04-17 |
| AU2010217605A1 (en) | 2011-08-18 |
| CN102333530A (zh) | 2012-01-25 |
| US20110306672A1 (en) | 2011-12-15 |
| BRPI1007994A2 (pt) | 2018-03-13 |
| CA2752003A1 (en) | 2010-09-02 |
| EP2400960A1 (en) | 2012-01-04 |
| RU2011138963A (ru) | 2013-04-10 |
| WO2010097371A1 (en) | 2010-09-02 |
| AU2010217605B2 (en) | 2012-07-26 |
| KR20110126631A (ko) | 2011-11-23 |
| US8673982B2 (en) | 2014-03-18 |
| ES2411138T3 (es) | 2013-07-04 |
| PL2400960T3 (pl) | 2013-08-30 |
| JP2012518671A (ja) | 2012-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
| WO2012056458A3 (en) | Intermediate compounds and process for the preparation of fingolimod | |
| IN2012DN01435A (enExample) | ||
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| MX373763B (es) | Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica. | |
| IN2012DN01434A (enExample) | ||
| HRP20200249T1 (hr) | Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol | |
| EA017091B9 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
| CL2011001405A1 (es) | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. | |
| GEP20156231B (en) | Agomelatine hydrochloride hydrate and preparation there of | |
| MX2011008876A (es) | Metabolitos analogos de ceramida. | |
| IL206197A (en) | Crystalline forms of the compound (r1, r2) –3– (3– dimethylamino – 1 – ethyl – 2 – methyl-profile) –phenol processes for their preparation, pharmaceutical compositions containing them, and their use in the preparation of pain treatment compositions | |
| BR112013028607A2 (pt) | composições sólidas contendo éter glicólico e água | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| CO6680629A2 (es) | Compuestos con actividad antibacteriana contra clsotridium | |
| MX2010009931A (es) | Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles. | |
| SG143203A1 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome | |
| MX361369B (es) | Modificaciones cristalinas estables de cloruro de dotap. | |
| WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
| ECSP13013043A (es) | Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma | |
| CO6361860A2 (es) | (beta)-hidroxi-y-aminofosfonatos y metodos para la preparacion y uso de los mismos | |
| IN2012DN06600A (enExample) | ||
| TN2010000584A1 (en) | Paediatric compositions for treating multiple scleoris | |
| TH149179A (th) | องค์ประกอบทางเภสัชกรรม, รูปแบบเภสัชภัณฑ์, กระบวนการในการเตรียมองค์ประกอบ และรูปแบบดังกล่าว, วิธีการในการรักษา และการใช้องค์ประกอบและรูปแบบดังกล่าว | |
| IN2013MU01225A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |